Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
AALL1521
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
- NCT02723994 ↗
- Completed
- Incyte Corporation
- Focused
We haven't built an HCP commentary report on AALL1521 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on AALL1521 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Leukemia
- Interventions
- Ruxolitinib; Asparaginase Erwinia Chrysanthemi; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Leucovorin Calcium; Mercaptopurine; Methotrexate; Pegaspargase; Prednisone; Thioguanine; Vincristine Sulfate
- Arms
- Ruxolitinib in combination with chemotherapy · Experimental
- Enrollment
- 171
- Primary outcomes
- Part 1: Safety/tolerability of ruxolitinib in combination with chemotherapy as measured by adverse events (AEs), vital signs, clinical laboratory tests, and echocardiograms
- Part 2: Efficacy of ruxolitinib in combination with chemotherapy as measured by Event-free survival, defined as the percentage of patients alive without relapse, progression, or death at 3 years from study Day 1
- Sponsor
- Incyte Corporation with Children's Oncology Group
- Start
- Sep 30, 2016
- Primary completion
- Mar 3, 2026
- Results posted
- No
- Registry record
- NCT02723994 · updated Mar 11, 2026